Disrupting cancer through SurVaxM immunotherapy

At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients

News and Events

Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy

First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM

“For years, we’ve struggled to move the needle as far as good treatment options for glioblastoma. Our hope is that SurVaxM will offer patients both longer survival and better quality of life,” says Dr. Abad, who is also an Assistant Professor of Oncology at Roswell Park. “To hopefully be on the precipice of meaningful progress against glioblastoma and to be able to possibly see my patients outside of the hospital — years after their diagnosis — would be incredible.”

February 4, 2022

MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma

MimiVax has received a “study may proceed” letter from the US-FDA to initiate Phase 2b “SURVIVE” study for newly diagnosed glioblastoma.

The Phase 2b “SURVIVE” clinical trial will evaluate SurVaxM in a randomized, blinded, placebo-controlled multi-center study to initially enroll at several U.S. sites. Additional sites in the United States and China to follow. 

November 15, 2021

Mimivax looks for game-changer in GBM as SurVaxM shows signal at interim look

In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint. 

May 21, 2018

MimiVax

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates

PartnerING

MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.

Pipeline

We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.

Clinical Trials

SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET). 

OUR MISSION

To disrupt cancer with innovative immunotherapies

SurVaxM is currently being evaluated in: a Phase 2b clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).

0
Clinical trials
0
Disease Indications
105
Patient Participants
1495
Doses Delivered

Disrupt cancer with the development of highly innovative immunotherapies

Partner with us

MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.

Contact us

To view a listing of investigational clinical trials open to patient enrollment that include SurVaxM, please visit clinicaltrials.gov.

For general inquiries: info@mimivax.com

Help accelerate the pace of SurvaxM clinical trials

The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.